Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

I-MAB - American Depositary Shares (NQ:IMAB)

2.130 -0.020 (-0.93%)
Streaming Delayed Price Updated: 11:24 AM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about I-MAB - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
What 4 Analyst Ratings Have To Say About I-MAB
Analysts have provided the following ratings for I-MAB (NASDAQ:IMAB) within the last quarter: 
Via Benzinga
This Analyst Cuts Price Target On Snap? Here Are 5 Other Price Target Changes For Wednesday
Citigroup cut the price target on Snap Inc. (NYSE: SNAP) from $16 to $10. Citigroup analyst Ronald Josey also downgraded the stock from Buy to Neutral. Snap shares fell 7% to $9.31 in pre-market... 
Via Benzinga
Earnings Scheduled For August 30, 2022
Companies Reporting Before The Bell • Photronics (NASDAQ:PLAB) is likely to report quarterly earnings at $0.50 per share on revenue of $210.00 million. 
Via Benzinga
Week In Review: China And The US May Settle De-Listing/Accounting Impasse
China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. The list of affected biopharma companies includes BeiGene, Legend Bio,... 
Via Talk Markets
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
  Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
This Analyst Cuts I-Mab's Price Target By 43%
I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.  
Via Benzinga
Needham Maintains Buy Rating for I-MAB: Here's What You Need To Know
  Needham has decided to maintain its Buy rating of I-MAB (NASDAQ:IMAB) and lower its price target from $72.00 to $41.00. Shares of I-MAB are trading down 15.43% over the last 24 hours, at $6.74 per... 
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga
AbbVie Calls Off Early-Stage Trial For I-Mab's CD47-Targeted Blood Cancer Candidate
Via Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session
Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022. 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of The Day Summary
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers Codex DNA, Inc. (NASDAQ: DNAY) rose 64.5% to $3.52 in pre-market trading after declining 10% on Tuesday. 
Via Benzinga
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global... 
Via Talk Markets
Week In Review: Fosun Pays $158 Million For Controlling Stake In Singapore Medical Centers
Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. Oncocare is one of Singapore’s largest private medical oncology... 
Via Talk Markets
83 Biggest Movers From Yesterday
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
HFCAA News: 128 Chinese Stocks the SEC Could Delist
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. 
Via InvestorPlace
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings... 
Via Talk Markets
Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products
Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.